We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
As a major manufacturer of methanic acid, according to the needs of international and domestic customers for Methanic acid drug density, particle size and other different specifications, our company on the basis of traditional Methanic acid powder, purchased advanced equipment and instruments, and has innovatively developed Methanic acid raw material product series: Methanic acid powder, particle, micro powder, heavy powder and other new products. The production process of this series of products is mature and has reached the international advanced level, which not only changes the situation of the monosyllabic acid specification in the pharmaceutical market, fills the gap of the diversification of the international market demand for methomic acid raw materials, breaks the technical barriers to trade and breaks the bottleneck of enterprise development, and is favored and recognized by the majority of customers in the international market. In recent years, our company has established a good long-term cooperative relationship with some well-known international enterprises, such as the United States Pfizer, France Sanofi, Brazil Novartis and other global well-known pharmaceutical companies have included our company in the qualified suppliers of methanic acid supply.
Methanic acid series products are 【 flufenic acid, chlorfenic acid, Tofenic acid, flunic acid and its derivatives (taniflurate, Morniflurate, butyl flufenate, Clonicoxin, Clonicin lysamate) 】 non-steroidal brain anti-inflammatory drugs. Steroidal anti-inflammatory drugs can produce moderate analgesic effect, and the analgesic effect site is mainly peripheral. It is good for chronic pain such as headache, joint muscle pain, toothache and so on. Anti-inflammatory drugs are drugs that inhibit the production or release of inflammatory factors. By inhibiting the production of inflammatory factors, inflammation can be reduced to subside, and the pain caused by inflammation can be relieved. Anti-inflammatory drugs are drugs used to treat inflammation, a reaction that occurs after tissue injury, and are usually referred to as antipyretic, analgesic and anti-inflammatory drugs in clinical practice. After the implementation of the project, the reaction yield of each product is 10-20% higher than that of the literature. The unit consumption of raw materials is significantly reduced, the by-products and solid waste generated by production are greatly reduced, and the purpose of cleaner production is achieved. Workshop equipment, facilities and other devices have reached the domestic advanced technology level. The quality of the products produced meets the international quality standards of the European Pharmacopoeia and the British Pharmacopoeia.
The company has many years of rich experience in the production of raw materials, through the improvement of existing products, high reaction conversion rate, less by-products, greatly reducing the pollution to the environment, industrial production operability, high safety factor. Through the research and application of new technologies and new processes, the company has become the world's largest methfenic acid API manufacturer, with exports accounting for more than 75% of the world.
Audited Supplier
Pharma Sources Insight JANUARY 2024
